Literature DB >> 31525930

Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).

Ute F Röhrig1, Aline Reynaud2, Somi Reddy Majjigapu1,3, Pierre Vogel3, Florence Pojer2, Vincent Zoete1,4.   

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metabolism, which is involved in immunity, neuronal function, and aging. Its implication in pathologies such as cancer and neurodegenerative diseases has stimulated the development of IDO1 inhibitors. However, negative phase III clinical trial results of the IDO1 inhibitor epacadostat in cancer immunotherapy call for a better understanding of the role and the mechanisms of IDO1 inhibition. In this work, we investigate the molecular inhibition mechanisms of four known IDO1 inhibitors and of two quinones in detail, using different experimental and computational approaches. We also determine for the first time the X-ray structure of the highly efficient 1,2,3-triazole inhibitor MMG-0358. Based on our results and a comprehensive literature overview, we propose a classification scheme for IDO1 inhibitors according to their inhibition mechanism, which will be useful for further developments in the field.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31525930     DOI: 10.1021/acs.jmedchem.9b00942

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Ute F Röhrig; Somi Reddy Majjigapu; Pierre Vogel; Aline Reynaud; Florence Pojer; Nahzli Dilek; Patrick Reichenbach; Kelly Ascenção; Melita Irving; George Coukos; Olivier Michielin; Vincent Zoete
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1.

Authors:  Emily C Cherney; Liping Zhang; Susheel Nara; Xiao Zhu; Johnni Gullo-Brown; Derrick Maley; Tai-An Lin; John T Hunt; Christine Huang; Zheng Yang; Celia Darienzo; Lorell Discenza; Asoka Ranasinghe; Mary Grubb; Theresa Ziemba; Sarah C Traeger; Xin Li; Kathy Johnston; Lisa Kopcho; Mark Fereshteh; Kimberly Foster; Kevin Stefanski; Joseph Fargnoli; Jesse Swanson; Jennifer Brown; Diane Delpy; Steven P Seitz; Robert Borzilleri; Gregory Vite; Aaron Balog
Journal:  ACS Med Chem Lett       Date:  2021-01-28       Impact factor: 4.345

3.  Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors.

Authors:  Derun Li; Yongqi Deng; Abdelghani Achab; Indu Bharathan; Brett Andrew Hopkins; Wensheng Yu; Hongjun Zhang; Sulagna Sanyal; Qinglin Pu; Hua Zhou; Kun Liu; Jongwon Lim; Xavier Fradera; Charles A Lesburg; Alfred Lammens; Theodore A Martinot; Ryan D Cohen; Amy C Doty; Heidi Ferguson; Elliott B Nickbarg; Mangeng Cheng; Peter Spacciapoli; Prasanthi Geda; Xuelei Song; Nadya Smotrov; Pravien Abeywickrema; Christine Andrews; Chad Chamberlin; Omar Mabrouk; Patrick Curran; Matthew Richards; Peter Saradjian; J Richard Miller; Ian Knemeyer; Karin M Otte; Stella Vincent; Nunzio Sciammetta; Alexander Pasternak; David Jonathan Bennett; Yongxin Han
Journal:  ACS Med Chem Lett       Date:  2021-02-26       Impact factor: 4.345

4.  Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.

Authors:  Yvonne Grobben; Jos de Man; Antoon M van Doornmalen; Michelle Muller; Nicole Willemsen-Seegers; Diep Vu-Pham; Winfried R Mulder; Martine B W Prinsen; Joeri de Wit; Jan Gerard Sterrenburg; Freek van Cauter; Judith E den Ouden; Anne M van Altena; Leon F Massuger; Joost C M Uitdehaag; Rogier C Buijsman; Guido J R Zaman
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

Review 5.  Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.

Authors:  Kai Tang; Ya-Hong Wu; Yihui Song; Bin Yu
Journal:  J Hematol Oncol       Date:  2021-04-21       Impact factor: 17.388

Review 6.  Jatrorrhizine: A Review of Sources, Pharmacology, Pharmacokinetics and Toxicity.

Authors:  Furong Zhong; Yang Chen; Jia Chen; Hailang Liao; Yirou Li; Yuntong Ma
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 7.  Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation.

Authors:  Chao Yang; Chan-Tat Ng; Dan Li; Lei Zhang
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

8.  Developing C2-Aroyl Indoles as Novel Inhibitors of IDO1 and Understanding Their Mechanism of Inhibition via Mass Spectroscopy, QM/MM Calculations and Molecular Dynamics Simulation.

Authors:  Jyoti Chauhan; Srinivas R Maddi; Kshatresh Dutta Dubey; Subhabrata Sen
Journal:  Front Chem       Date:  2021-07-15       Impact factor: 5.221

9.  Temporary Intermediates of L-Trp Along the Reaction Pathway of Human Indoleamine 2,3-Dioxygenase 1 and Identification of an Exo Site.

Authors:  Manon Mirgaux; Laurence Leherte; Johan Wouters
Journal:  Int J Tryptophan Res       Date:  2021-12-15

10.  The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors.

Authors:  Silvia Fallarini; Irene P Bhela; Silvio Aprile; Enza Torre; Alice Ranza; Elena Orecchini; Eleonora Panfili; Maria T Pallotta; Alberto Massarotti; Marta Serafini; Tracey Pirali
Journal:  ChemMedChem       Date:  2021-08-27       Impact factor: 3.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.